Future for biological therapy for uveitis

James T. Rosenbaum

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


Purpose of review: To review biological therapies as they pertain to the treatment of inflammatory eye diseases, especially uveitis. Recent findings: Biological therapies including antibodies, soluble receptors, and cytokines are being tested increasingly for a variety of ocular inflammations. As a class, tumor necrosis factor inhibitors have arguably been the most widely employed and have emerged as a successful approach to treat Behçet's disease. Alpha interferon has demonstrated efficacy in the treatment of Behçet's disease and other forms of posterior uveitis. Additional cytokines, cell surface markers, adhesion molecules, and accessory molecules are targets of biological therapy, but the relevance of these targets in eye inflammation is sometimes just theoretical. And any disruption of the immune response entails potential risk. Summary: Biological therapies offer tremendous potential in the treatment of ocular inflammation, but their study to date has been limited and both the efficacy and the risk are incompletely known for most of the available interventions.

Original languageEnglish (US)
Pages (from-to)473-477
Number of pages5
JournalCurrent opinion in ophthalmology
Issue number6
StatePublished - Nov 1 2010


  • accessory molecules
  • adhesion molecules
  • biologics
  • tumor necrosis factor
  • uveitis

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Future for biological therapy for uveitis'. Together they form a unique fingerprint.

Cite this